"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Pfizer appoints former J&J executive to lead obesity drug development Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

boosting the prospects of the company that is in the process of being acquired by Pfizer Inc . Seagen's breast cancer therapy succeeds in late-stage study Healthcare & Pharmaceuticalscategory ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.

Analysts expect Pfizer to post earnings of $0.48 per share and revenue of $17,264,454.90 billion for the quarter. Persons interested in participating in the company’s earnings conference call ...

I believe shorting now lacks an asymmetric risk-reward profile ... To wrap up, I rate Pfizer as a sell considering a timeframe of 18–24 months. This year, the company is expecting a $1 billion ...

The combination therapy's safety profile was also addressed ... reduced its price target for Pfizer from $33 to $32, maintaining a "Buy" rating, following the company's recent earnings report.

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.